Journal of geriatric oncology最新文献

{"title":"Getting the right measure: Gait speed assessment and outcomes in older patients with cancer","authors":"Evelien R.A. Spruijt ,&nbsp;Ajay T. Bakas ,&nbsp;Aniel Sewnaik ,&nbsp;Christian Oudshoorn ,&nbsp;Francesco Mattace-Raso ,&nbsp;Rob J. Baatenburg de Jong ,&nbsp;Harmke A. Polinder-Bos","doi":"10.1016/j.jgo.2026.102908","DOIUrl":"10.1016/j.jgo.2026.102908","url":null,"abstract":"<div><h3>Introduction</h3><div>Gait speed (GS) reflects an individual's physical capacity and is often used to assess the level of fitness in older individuals with cancer. Importantly, GS can be measured in various ways. This study examined the association between several GS measurements and one-year mortality in older patients with head and neck cancer.</div></div><div><h3>Materials and methods</h3><div>This prospective cohort study included 227 patients. GS was measured at usual and fast pace using a 5-m walkway. GS reserve (fast-usual GS) and GS ratio (fast/usual GS) were calculated. GS measurements were analyzed both as continuous and categorical variables. For the categorical analyses, two categorical GS variables were created: ‘1 m/s’ and ‘25th percentile.’ Each variable included three categories: for ‘1 m/s’: usual and fast GS &lt;1 m/s, usual GS &lt;1 m/s and fast GS ≥1 m/s, and usual and fast GS ≥1 m/s; for ‘25th-percentile’: usual and fast GS &lt; p25, usual GS &lt; p25 and fast GS ≥ p25, and usual and fast GS ≥ p25. Cox regression survival analyses were performed.</div></div><div><h3>Results</h3><div>Median age was 76 [IQR 72–80] years, 71% were men and 51 patients died within one year. Mean usual and fast GS were 1.08 ± 0.27 and 1.41 ± 0.39 m/s, respectively. A higher usual (HR 0.23, 95%CI 0.07–0.76) or fast GS (HR 0.36, 95%CI 0.14–0.91) were associated with lower mortality. Patients with usual and fast GS &lt;1 m/s (HR 2.66, 95%CI 1.29–5.50) had a higher mortality risk compared to patients with usual and fast GS &gt;1 m/s. The association of 25th percentile group with mortality attenuated after adjustment for treatment (HR 2.07, 95%CI 0.91–4.73). Neither GS reserve nor GS ratio were associated with mortality.</div></div><div><h3>Discussion</h3><div>Lower usual and fast gait speeds are associated with higher one-year mortality in patients with head and neck cancer. A simple guideline is that patients with usual and fast GS &lt;1 m/s or &lt; p25 have a twofold higher risk of dying within one year compared to patients who walk faster.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102908"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147306745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What nutritional interventions can effectively treat sarcopenia in older adults with cancer? A systematic review","authors":"Megan Pattwell ,&nbsp;Michelle Gibbs ,&nbsp;Colm Mac Eochagáin ,&nbsp;Emma Crewe ,&nbsp;Anne Barrell ,&nbsp;Erin Stella Sullivan ,&nbsp;Hannah Furness ,&nbsp;Ione de Brito-Ashurst ,&nbsp;Susanne Cruickshank ,&nbsp;Nicolò Matteo Luca Battisti","doi":"10.1016/j.jgo.2026.102850","DOIUrl":"10.1016/j.jgo.2026.102850","url":null,"abstract":"<div><h3>Introduction</h3><div>Cancer primarily affects older adults, with a significant proportion also experiencing sarcopenia which is associated with poor clinical outcomes. In older adults with cancer, sarcopenia is not only age-related but also exacerbated by disease processes, inflammation, and the catabolic effects of treatments such as chemotherapy and radiotherapy. Its presence is linked to increased treatment toxicity, longer hospitalisations, reduced physical function, and poorer survival rates. However, diagnosing sarcopenia remains challenging due to inconsistent criteria and limited access to diagnostic tools. Emerging evidence suggests that nutritional interventions may help prevent or reverse sarcopenia. This review aims to evaluate the effectiveness of nutritional interventions in managing sarcopenia in older adults with cancer.</div></div><div><h3>Materials and methods</h3><div>A systematic review was conducted using the PICO framework, targeting studies involving patients aged 65 and older with cancer and confirmed or likely sarcopenia. A total of 1439 studies were retrieved from databases and screened using Rayyan. Data extraction focused on outcomes related to body composition, physical performance, and nutritional intake. Risk of bias was assessed using RoB2, ROBINS-I, and ROBINS-E tools. Due to heterogeneity in study designs and outcome measures, a narrative synthesis was performed using SWiM guidelines. Studies were grouped by design and intervention type, and the GRADE approach was applied to assess evidence certainty.</div></div><div><h3>Results</h3><div>Nine studies (2016–2024) met the inclusion criteria. Interventions included dietary supplements, nutritional counselling, enteral feeding, and multimodal strategies. Most studies showed improvements in sarcopenia-related outcomes. Protein supplementation notably improved lean body mass and skeletal muscle index in some randomised control trials (RCTs). Observational studies found associations between certain dietary patterns—such as high fish and fat intake—and reduced sarcopenia risk.</div></div><div><h3>Discussion</h3><div>Nutritional interventions show promise in managing sarcopenia among older adults with cancer. However, further large-scale, standardised research is needed. Meanwhile, promoting good nutrition and physical activity remains essential.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102850"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a new model for prediction of relevant treatment related adverse events in older individuals with gastrointestinal cancers","authors":"Vallish Shenoy ,&nbsp;Sadhana Kannan ,&nbsp;Vanita Noronha ,&nbsp;Kumar Prabhash ,&nbsp;Vikas Ostwal ,&nbsp;Prabhat Bhargava ,&nbsp;Anupa Pillai ,&nbsp;K. Shamseeya ,&nbsp;Ankush Shetake ,&nbsp;Ratan Dhekale ,&nbsp;Ankita Chitre ,&nbsp;Vikram Gota ,&nbsp;Sarika Mahajan ,&nbsp;Anuradha Daptardar ,&nbsp;Lekhika Sonkusare ,&nbsp;Jayita Deodhar ,&nbsp;Nabila Ansari ,&nbsp;Manjusha Vagal ,&nbsp;Purabi Mahajan ,&nbsp;Manjunath Nookala ,&nbsp;Anant Ramaswamy","doi":"10.1016/j.jgo.2025.102817","DOIUrl":"10.1016/j.jgo.2025.102817","url":null,"abstract":"<div><h3>Introduction</h3><div>Limited tools exist to specifically predict the risk of chemotherapy toxicity and related events in older individuals with gastrointestinal (GI) cancers.</div></div><div><h3>Materials and Methods</h3><div>We evaluated patients aged ≥60 years with GI cancers who underwent a comprehensive geriatric assessment comprising demographic, cancer variables, and geriatric domains (function, comorbidities, nutritional status, medications, cognition, psychological status, and social support). A Cancer and Aging Research Group (CARG) score was calculated in all patients. The occurrence of grade 3 to 5 adverse events, emergent hospitalizations, and sudden death without identifiable adverse events were defined as treatment related adverse events (TRAE) to form the new predictive model. Based on initial univariate analysis of factors predicting for TRAE and then multivariate analysis, a nomogram was developed to predict the probability TRAEs. The total score derived from the nomogram was categorized into low, moderate, and high-risk groups based on a recursive partitioning algorithm.</div></div><div><h3>Results</h3><div>In total, 701 patients with a median age of 67 years (range, 60 to 88 years) with predominantly stage IV cancers (58 %) were analysed. The distribution of GI cancers was gastric and esophageal cancers (<em>n</em> = 349, 50 %), hepatobiliary and pancreatic cancers (<em>n</em> = 241, 34 %), and colorectal cancers (<em>n</em> = 84, 12 %). TRAE occurred in 53 % of the patients. A predictive model for TRAE was developed using the Mobility-Tiredness (Mob-T) Scale, hearing, cancer stage, site of primary, and chemotherapy dosing (standard or reduced). A predictive score in which the median risk score was 22 (range, 0 to 40) and risk stratification identified older adults at low risk (0 to 13 points; 17 %), intermediate risk (14 to 21 points; 40 %), or high risk (&gt;22 points; 71 %) of chemotherapy toxicity (<em>P</em> &lt; 0.001). The new model outperformed the CARG score based on ROC analysis (0.75 vs 0.59, <em>p</em> &lt; 0.001).</div></div><div><h3>Discussion</h3><div>A new and simpler risk score predicts for chemotherapy related adverse events in older patients with GI cancers and seems to be more accurate than the CARG score. The score requires validation in prospective studies.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102817"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145692903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dizziness and impaired postural balance in older patients receiving chemotherapy treatment: A systematic review and meta-analysis","authors":"Katrine Storm Piper ,&nbsp;Martine Puts ,&nbsp;Cecilia Lund ,&nbsp;Jesper Ryg ,&nbsp;Charlotte Suetta ,&nbsp;Hanne Elkjær Andersen ,&nbsp;Jakob Vasehus Schou ,&nbsp;Allan Madsen ,&nbsp;Jan Christensen","doi":"10.1016/j.jgo.2025.102816","DOIUrl":"10.1016/j.jgo.2025.102816","url":null,"abstract":"<div><h3>Introduction</h3><div>Dizziness and balance impairments are underexplored symptoms in older adults with cancer. Age-related factors, comorbidities, and chemotherapy may contribute to its prevalence and severity, potentially affecting quality of life, increasing fall risk, and delaying treatment. Data on the incidence and prevalence of these symptoms are limited. This systematic review aimed to summarize the evidence and estimate the incidence and prevalence of dizziness or vertigo and impaired postural balance in patients with cancer ≥65 years receiving chemotherapy.</div></div><div><h3>Materials and Methods</h3><div>We searched PubMed, EMBASE, CENTRAL, and CINAHL in May 2025 without date or language restrictions. Cross sectional studies, cohort studies, randomized controlled trials, and mixed method studies investigating incidence and/or prevalence of dizziness or vertigo and impaired postural balance were included. Random-effects meta-analysis, employing the inverse-variance method, was applied. Certainty of evidence was rated by the Grading of Recommendations Assessment and Evaluation (GRADE) approach.</div></div><div><h3>Results</h3><div>From 15,614 title/abstracts screened, 14 studies (1259 participants) were included. Incidence could not be evaluated. Studies reporting prevalence across multiple chemotherapy regimens contributed separate estimates for each regimen. Meta-analysis included 25 prevalence estimates for dizziness and three for impaired postural balance. The pooled prevalence of dizziness was 15 % (95 % CI:10 %–22 %). Assessor-reported prevalence using the Common Terminology Criteria for Adverse Events (CTCAE) was 11 % (95 % CI: 8 %–16 %), while patient-reported prevalence rate using the European Organisation for Research and Treatment of Cancer Chemotherapy Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20), or a self-constructed questionnaire was 35 % (95 % CI: 20 %–53 %). Most studies demonstrated a high risk of bias, and certainty of evidence was very low due to unstructured assessor-reported measurement methods. Impaired postural balance prevalence from one study was 48 % (95 % CI: 39 %–57 %) with low certainty of evidence. Prevalence of dizziness and impaired postural balance did not differ significantly across chemotherapy regimens.</div></div><div><h3>Discussion</h3><div>Prevalence of dizziness and impaired postural balance in older patients receiving chemotherapy varied substantially depending on the measurement method, with higher rates in patient-reported outcomes. Certainty of evidence was low primarily due to limitations in outcome measures. Future studies should incorporate patient-reported outcome measures and a systematic objective baseline assessment for a comprehensive evaluation of these symptoms.</div><div>Trial registration: PROSPERO CRD42024585974.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102816"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145692902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of geriatric assessment and management recommendations for older adults with non-small cell lung cancer (NSCLC) receiving chemotherapy/radiation treatment (GAM-CRT): A preliminary analysis","authors":"C. Presley ,&nbsp;H. Antao ,&nbsp;M. Grogan ,&nbsp;V. Katheria ,&nbsp;C. Sun ,&nbsp;H. Kim ,&nbsp;L. Mitchell ,&nbsp;J. Loubes ,&nbsp;B. Wind ,&nbsp;A. Pannella ,&nbsp;V. Branch ,&nbsp;L. Lupercio ,&nbsp;D. Spakowicz ,&nbsp;C. Burd ,&nbsp;M. Wong ,&nbsp;A. Amini ,&nbsp;W. Dale ,&nbsp;S. Mohile","doi":"10.1016/j.jgo.2026.102888","DOIUrl":"10.1016/j.jgo.2026.102888","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102888"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes and toxicity of immune checkpoint inhibitors (ICIs) in advanced bladder cancer: A real-world study in geriatric Asian population","authors":"H.S. Tan ,&nbsp;J.X.J. Tan ,&nbsp;X.H. Tan ,&nbsp;Q.S. Ng ,&nbsp;J. Chan ,&nbsp;W.C. Tan ,&nbsp;A. Roy Chowdhury ,&nbsp;R. Kanesvaran","doi":"10.1016/j.jgo.2026.102881","DOIUrl":"10.1016/j.jgo.2026.102881","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102881"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147449059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety profile of immunotherapy in patients aged ≥70 years: Real-world data","authors":"I. Furtado,&nbsp;R. Ferreira,&nbsp;R. Escaleira,&nbsp;F. Verdasca,&nbsp;M. Seladas,&nbsp;N. Nogueira,&nbsp;A.J. Fernandes,&nbsp;L. Coelho,&nbsp;A. Montenegro","doi":"10.1016/j.jgo.2026.102875","DOIUrl":"10.1016/j.jgo.2026.102875","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102875"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147449069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary endpoints in randomized controlled trials for older adults with cancer: A scoping review","authors":"Tomonori Mizutani ,&nbsp;Funato Sato ,&nbsp;Kohei Uemura ,&nbsp;Yukari Shimizu ,&nbsp;Tsuguo Iwatani ,&nbsp;Satoshi Kobayashi ,&nbsp;Masataka Sawaki ,&nbsp;Shimon Tashiro ,&nbsp;Tetsuya Tsuji ,&nbsp;Hiroshi Yamamoto ,&nbsp;Asao Ogawa ,&nbsp;Tetsuya Hamaguchi ,&nbsp;on behalf of the Geriatric Study Committee of the Japan Clinical Oncology Group, Japan","doi":"10.1016/j.jgo.2026.102895","DOIUrl":"10.1016/j.jgo.2026.102895","url":null,"abstract":"<div><h3>Introduction</h3><div>Older adults represent a growing proportion of patients with cancer. However, confirmatory randomized controlled trials (RCTs) continue to rely primarily on tumor-based endpoints such as overall survival (OS), which may overlook outcomes particularly important to older adults, including quality of life (QOL), functional status, and treatment tolerance. This review aimed to systematically characterize the primary endpoints used in confirmatory RCTs enrolling adults aged ≥65 years and to evaluate how novel endpoints reflecting patient priorities were defined and analyzed.</div></div><div><h3>Materials and methods</h3><div>PubMed, CINAHL, and the Cochrane Library were searched for English-language confirmatory RCTs exclusively enrolling adults aged ≥65 years with cancer and reporting a primary endpoint (up to January 19, 2024). Endpoints were classified as conventional (tumor-based) or novel (non-tumor-based). Data were extracted on endpoint definitions, measurement tools, and statistical approaches.</div></div><div><h3>Results</h3><div>Of 822 records identified, 66 RCTs met the eligibility criteria, yielding 71 primary endpoints. Conventional outcomes predominated (<em>n</em> = 53; 74.6%), with OS being the most frequent, followed by progression-free survival and disease-free survival. Novel endpoints (<em>n</em> = 18; 25.3%) included health-related QOL (HR-QOL), toxicity, geriatric assessment–based measures, composite endpoints, and patient satisfaction. HR-QOL was most commonly assessed using the European Organization for Research and Treatment of Cancer QLQ-C30. Definitions of toxicity and functional decline varied across studies. Variance assumptions were rarely reported, and minimal clinically important differences were inconsistently applied. Additional endpoints, such as quality-adjusted survival, overall treatment utility, and disability-free survival, were infrequently reported.</div></div><div><h3>Discussion</h3><div>Survival remains the predominant endpoint in confirmatory RCTs involving older adults with cancer, while patient-relevant outcomes are inconsistently incorporated. Addressing these gaps may facilitate more patient-centered trial designs and improve the real-world applicability of research findings for the aging cancer population.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102895"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146078059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review of frailty, functional status & comorbidities in older adults with multiple myeloma undergoing high dose therapy & autologous stem cell transplant","authors":"Nadine Abdallah ,&nbsp;Ashlyn O’Leary ,&nbsp;Cynthia M. Schmidt ,&nbsp;Sikander Ailawadhi ,&nbsp;Hira Mian ,&nbsp;Ashley Rosko ,&nbsp;Tanya M. Wildes","doi":"10.1016/j.jgo.2025.102846","DOIUrl":"10.1016/j.jgo.2025.102846","url":null,"abstract":"<div><h3>Introduction</h3><div>Improvements in supportive care strategies and growing evidence for benefit have led to increased use of autologous stem cell transplant (ASCT) in older patients with multiple myeloma (MM). However, the lack of standardized criteria for transplant eligibility often leaves the decision to the physician's clinical judgment. The roles of frailty/geriatric assessment tools, functional status, and comorbidity in selecting candidates and predicting transplant outcomes in older patients with MM remain uncertain. The purpose of this systematic review was to examine the measures of frailty, functional status, and comorbidity reported for older patients with MM who underwent ASCT and to evaluate their association with outcomes.</div></div><div><h3>Materials and methods</h3><div>On April 11, 2024, MEDLINE, EMBASE, and the Cochrane Library were searched for articles that included older adults (&gt;60 years) with MM addressing the use of ASCT or ASCT eligibility/ineligibility. We included retrospective and prospective studies that included (1) at least one measure of functional status and/or comorbidities and (2) at least one transplant-related outcome (response rate, transplant-related mortality).</div></div><div><h3>Results</h3><div>Twenty-five studies were included, four prospective and 21 retrospective. Of these, four studies utilized the International Myeloma Working Group (IMWG) frailty index, with some including frail patients. In one study utilizing a comprehensive geriatric assessment, &gt;50 % of older adults who were considered transplant-eligible reported dependence on ≥1 Instrumental Activities of Daily Living (IADL), severe limitations in vigorous activities, and/or self-reported weight loss. Eighteen studies reported a measure of functional status, most commonly Eastern Cooperative Oncology Group Performance Status; 19 studies reported a comorbidity measure, most commonly Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI). The comorbidity scores were generally low in patients who underwent ASCT (&lt;3). The 100-day treatment-related mortality ranged from 0 % to 6 %, with overall response rates were generally high across studies.</div></div><div><h3>Discussion</h3><div>There is wide variability in the tools used to assess characteristics of older adults who underwent ASCT across studies. The optimal tool for selecting older ASCT candidates remains undefined, but it is likely that no single measure can adequately capture overall health status. Prospective studies incorporating a multidimensional assessment are necessary to better define transplant eligibility in this population.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102846"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-existing autoimmune disease and risk of immune checkpoint inhibitor (ICI) discontinuation in older adults with melanoma","authors":"S. Sharma ,&nbsp;H. Yao ,&nbsp;K. Gandhi ,&nbsp;A.L. Shaver ,&nbsp;S.W. Keith ,&nbsp;R.S. Seedor ,&nbsp;N. Nikita","doi":"10.1016/j.jgo.2026.102870","DOIUrl":"10.1016/j.jgo.2026.102870","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102870"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}